Reference Population for Speckle Tracking Imaging

Establishing a Reference Population for Normal Left Ventricular Function Parameters to Validate the Use of Two Dimensional Speckle Tracking Imaging Software in the Scar Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01526252

Acronym

STE Normal

Enrollment

Registered

2012-02-03

Start date

2011-12-31

Completion date

2015-01-31

Last updated

2017-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Function

Keywords

speckle tracking echocardiography, database

Brief summary

The SCAR study uses a software program entitled QLAB, a proprietory program, developed by Philips Healthcare (Philips Healthcare, Andover, MA). Literature on two-dimensional speckle tracking imaging (2DSTE) is growing, but data relevant to the population in the SCAR study is minimal. Accumulation of data relevant for a population of subjects will provide a set of normal values for interpretation of 2DSTE and minimize any influences from differences in data produced from different companies. This data may also assist other researchers investigate other cardiac diseases and abnormalities.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Be between the ages of 20 - 80 years at study entry * Provide written informed consent and be able to comply with study procedures, including permission to access medical records * Have a BMI index equal to or less than 35 * Less than 5% risk of developing coronary artery disease as determined using the Combined Diamond/Forrester and CASS data (ACC Stable CAD Guidelines)

Exclusion criteria

* Have taken cardioactive drugs within 6 months prior to examination * These include but are not limited to beta-blockers, calcium channel blockers, and angiotensin converting enzyme inhibitors * Currently clinically significant chronic or acute illness * Documented cardiovascular disease * Possess abnormal cardiac structure and function after examination with routine ECHO * This may include valvular defects, left ventricular hypertrophy, cardiomyopathies or pericardial disease * Documented congenital heart conditions or defects * History of diabetes * Be unwilling to provide voluntary consent

Design outcomes

Primary

Measure	Time frame
Establishment of normal values data in males and females aged 20 - 80	1 year

Countries

Canada

Outcome results